Please login to the form below

Not currently logged in
Email:
Password:

FDA approves Onglyza

Type 2 diabetes treatment from AstraZeneca and Bristol-Myers Squibb gets approval in the US

AstraZeneca and Bristol-Myers Squibb (BMS) have received US Food and Drug Administration (FDA) approval for Onglyza (saxagliptin) for the treatment of type 2 diabetes mellitus in adults.

Onglyza is indicated as an adjunct to diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. The once-daily dipeptidyl peptidase-4 (DPP-4) can be used in combination with commonly prescribed oral anti-diabetic medications, such as metformin, sulfonylureas and thiazolidinediones (TZDs), or as a monotherapy to significantly reduce glycosylated haemoglobin levels.

"Type 2 diabetes is a daily challenge for adults patients and physicians. With FDA approval of Onglyza, physicians and adult patients with type 2 diabetes have an important new treatment to help improve glycemic control," said David Brennan, AstraZeneca CEO.

DPP-4 affect the action of incretins; hormones that decrease elevated blood sugar levels by increasing the way the body uses sugar, mainly through increasing insulin production in the pancreas and by reducing the production of glucose in the liver.

The collaboration between AstraZeneca and BMS began in January 2007 with the aim of enabling the two companies to research, develop and commercialise select investigational drugs for type 2 diabetes. 

3rd August 2009

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics